InMed Pharmaceuticals Inc. INM
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -60.74% | -34.06% | -6.73% | -3.27% | 7.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -60.74% | -34.06% | -6.73% | -3.27% | 7.50% |
| Cost of Revenue | -4.85% | -39.57% | -56.66% | -59.62% | -59.33% |
| Gross Profit | -38.45% | -58.65% | -65.65% | -45.07% | -13.32% |
| SG&A Expenses | 19.77% | -6.15% | -5.53% | 1.70% | 4.43% |
| Depreciation & Amortization | -2.46% | -1.87% | -3.27% | -4.15% | -3.60% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.22% | -9.93% | -22.41% | -16.96% | -19.21% |
| Operating Income | -25.30% | -6.95% | -0.88% | -9.02% | 2.75% |
| Income Before Tax | -39.68% | -1.59% | 3.16% | -20.47% | -6.34% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -39.68% | -1.50% | 3.24% | -20.35% | -6.24% |
| Earnings from Discontinued Operations | -15,306.58% | -138.03% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -53.89% | -2.38% | 3.15% | -20.46% | -6.34% |
| EBIT | -25.30% | -6.95% | -0.88% | -9.02% | 2.75% |
| EBITDA | -26.06% | -7.24% | -1.02% | -9.45% | 2.71% |
| EPS Basic | 70.73% | 76.62% | 70.78% | 48.60% | 64.31% |
| Normalized Basic EPS | 76.37% | 76.60% | 70.87% | 48.67% | 64.36% |
| EPS Diluted | 70.73% | 76.62% | 70.78% | 48.60% | 64.31% |
| Normalized Diluted EPS | 76.37% | 76.60% | 70.87% | 48.67% | 64.36% |
| Average Basic Shares Outstanding | 341.83% | 363.37% | 358.97% | 266.25% | 156.61% |
| Average Diluted Shares Outstanding | 341.83% | 363.37% | 358.97% | 266.25% | 156.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |